Literature DB >> 33750399

Modelling the association between COVID-19 transmissibility and D614G substitution in SARS-CoV-2 spike protein: using the surveillance data in California as an example.

Shi Zhao1,2, Jingzhi Lou1, Lirong Cao1, Hong Zheng1, Marc K C Chong1,2, Zigui Chen3, Benny C Y Zee1,2, Paul K S Chan3, Maggie H Wang4,5.   

Abstract

BACKGROUND: The COVID-19 pandemic poses a serious threat to global health, and pathogenic mutations are a major challenge to disease control. We developed a statistical framework to explore the association between molecular-level mutation activity of SARS-CoV-2 and population-level disease transmissibility of COVID-19.
METHODS: We estimated the instantaneous transmissibility of COVID-19 by using the time-varying reproduction number (Rt). The mutation activity in SARS-CoV-2 is quantified empirically depending on (i) the prevalence of emerged amino acid substitutions and (ii) the frequency of these substitutions in the whole sequence. Using the likelihood-based approach, a statistical framework is developed to examine the association between mutation activity and Rt. We adopted the COVID-19 surveillance data in California as an example for demonstration.
RESULTS: We found a significant positive association between population-level COVID-19 transmissibility and the D614G substitution on the SARS-CoV-2 spike protein. We estimate that a per 0.01 increase in the prevalence of glycine (G) on codon 614 is positively associated with a 0.49% (95% CI: 0.39 to 0.59) increase in Rt, which explains 61% of the Rt variation after accounting for the control measures. We remark that the modeling framework can be extended to study other infectious pathogens.
CONCLUSIONS: Our findings show a link between the molecular-level mutation activity of SARS-CoV-2 and population-level transmission of COVID-19 to provide further evidence for a positive association between the D614G substitution and Rt. Future studies exploring the mechanism between SARS-CoV-2 mutations and COVID-19 infectivity are warranted.

Entities:  

Keywords:  COVID-19; Mutation; Spike protein; Statistical modeling; Transmission

Year:  2021        PMID: 33750399      PMCID: PMC7941367          DOI: 10.1186/s12976-021-00140-3

Source DB:  PubMed          Journal:  Theor Biol Med Model        ISSN: 1742-4682            Impact factor:   2.432


  5 in total

1.  Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2.

Authors:  Shi Zhao; Jingzhi Lou; Marc K C Chong; Lirong Cao; Hong Zheng; Zigui Chen; Renee W Y Chan; Benny C Y Zee; Paul K S Chan; Maggie H Wang
Journal:  Viruses       Date:  2021-04-08       Impact factor: 5.048

2.  The co-circulating transmission dynamics of SARS-CoV-2 Alpha and Eta variants in Nigeria: A retrospective modeling study of COVID-19.

Authors:  Shi Zhao; Salihu S Musa; Marc Kc Chong; Jinjun Ran; Mohammad Javanbakht; Lefei Han; Kai Wang; Nafiu Hussaini; Abdulrazaq G Habib; Maggie H Wang; Daihai He
Journal:  J Glob Health       Date:  2021-12-25       Impact factor: 4.413

3.  Quantifying the effect of government interventions and virus mutations on transmission advantage during COVID-19 pandemic.

Authors:  Jingzhi Lou; Hong Zheng; Shi Zhao; Lirong Cao; Eliza Ly Wong; Zigui Chen; Renee Wy Chan; Marc Kc Chong; Benny Cy Zee; Paul Ks Chan; Eng-Kiong Yeoh; Maggie H Wang
Journal:  J Infect Public Health       Date:  2022-02-04       Impact factor: 3.718

Review 4.  Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19).

Authors:  Ting Wu; Shuntong Kang; Wenyao Peng; Chenzhe Zuo; Yuhao Zhu; Liangyu Pan; Keyun Fu; Yaxian You; Xinyuan Yang; Xuan Luo; Liping Jiang; Meichun Deng
Journal:  Front Med (Lausanne)       Date:  2021-07-06

5.  The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: A conceptual model for COVID-19.

Authors:  Shi Zhao; Kai Wang; Marc K C Chong; Salihu S Musa; Mu He; Lefei Han; Daihai He; Maggie H Wang
Journal:  J Theor Biol       Date:  2022-03-21       Impact factor: 2.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.